Table 2. Univariate and multivariate Cox regression analysis of CYP4A+ TAM counts for overall survival of breast cancer patients in the tissue array.
| Characteristics |
Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age (⩽54 vs >54) | 1.957 (0.924–4.146) | 0.080 | ||
| Pathological grade (I–II vs III) | 2.170 (1.044–4.514) | 0.038* | 1.097 (0.420–2.865) | 0.850 |
| T stage (T1 vs T2–T3) | 1.312 (0.610–2.822) | 0.487 | ||
| ER (negative vs positive) | 0.319 (0.153–0.662) | 0.002* | 0.361 (0.150–0.868) | 0.023* |
| PR (negative vs positive) | 0.724 (0.348–1.504) | 0.386 | ||
| Her-2 (negative vs positive) | 0.381 (0.159–0.912) | 0.030* | 0.405 (0.166–0.989) | 0.047* |
| Lymph node metastasis (0 vs ⩾1) | 2.789 (1.270–6.128) | 0.011* | 1.835 (0.793–4.245) | 0.156 |
| TNM stage (I vs II–III) | 2.954 (0.894–9.764) | 0.076 | ||
| CYP4A+ TAMs counts (low vs high) | 2.227 (1.035–4.791) | 0.041* | 2.135 (0.809–5.637) | 0.126 |
Abbreviations: CI, confidence interval; ER, estrogen receptor; Her-2, human epidermal growth factor receptor-2; HR, hazard ratio; PR, progesterone receptor; TNM, tumor node metastasis.
*P<0.05.